Geoffrey Shapiro, M.D., Ph.D., is director of the Early Drug Development Center, clinical director of the Center for DNA Damage and Repair and an institute physician at Dana-Farber Cancer Institute. He is also co-leader of the Dana-Farber/Harvard Cancer Center (DF/HCC) Program in Developmental Therapeutics and a professor of medicine at Harvard Medical School.
Geoffrey joined the Dana-Farber faculty in 1994, where his research focuses on identifying cell-cycle-related targets for antitumor drug development. He conducts both basic and translational research on cyclin-dependent kinase inhibitors and is currently directing both preclinical and clinical studies of several potent pharmacologic cyclin-dependent kinase inhibitors.
Within the DF/HCC Developmental Therapeutics Program, Geoffrey leads collaborative activities with the National Cancer Institute-Cancer Therapy Evaluation Program (NCI-CTEP) and has developed many trials using inhibitors of signal transduction, cell cycle, DNA repair and immunologic targets currently conducted by the U.S. Experimental Therapeutics Clinical Trials Network (ETCTN).
A board-certified oncologist, Dr. Shapiro received his Ph.D. and M.D. from the Weill Medical College of Cornell University, followed by postgraduate training in internal medicine at Beth Israel Hospital, Boston, where he served as chief medical resident. He completed a fellowship in medical oncology at Dana-Farber Cancer Institute, during which he investigated the role of cell-cycle-related proteins in lung cancer.